Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3

This study has been terminated.
Information provided by:
Rigshospitalet, Denmark Identifier:
First received: January 5, 2006
Last updated: September 17, 2009
Last verified: September 2009

January 5, 2006
September 17, 2009
January 1998
Not Provided
Same as current
Complete list of historical versions of study NCT00273507 on Archive Site
  • Time to progression
  • Complete resection rate
Same as current
Not Provided
Not Provided
Neoadjuvant Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Stages IB, IIA, IIB, and IIIA/T3
Neoadjuvant Chemotherapy in Resectable NSCLC Stages IB, IIA, IIB, and IIIA/T3 But Not IIIA/N2
Randomised trial of chemotherapy or not before surgery in early resectable stages of NSCLC (IB, IIA, IIB, and IIIA/N2).
Randomisation between 3 courses of neoadjuvant Carboplatin plus Paclitaxel or no chemotherapy before surgery.
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Non-small Cell Lung Cancer
Drug: Carboplatin and Paclitaxel
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2006
Not Provided

Inclusion Criteria:

  • Stages IB, IIA, IIB, IIIA/T3
  • Lung function test allowing surgery
  • Age 18-75 years

Exclusion Criteria:

  • Poor lung function
  • Performance status 3-4
  • Mediastinal lymph node involvement
18 Years to 75 Years
Contact information is only displayed when the study is recruiting subjects
Neoadjuvant treatment in NSCLC
Not Provided
Not Provided
Rigshospitalet, Denmark
Not Provided
Study Chair: Jens B. Sorensen, MD Dept. Oncology, Rigshospitalet
Rigshospitalet, Denmark
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP